Results 361 to 370 of about 4,836,823 (371)

Intravitreal anti-VEGF agents and cardiovascular risk

Internal and Emergency Medicine, 2019
M. Porta, E. Striglia
semanticscholar   +1 more source

The Utility of Anti-Inflammatory Agents in Cardiovascular Disease

Journal of Cardiovascular Pharmacology and Therapeutics, 2018
Santhosh J. Kottoor, R. Arora
semanticscholar   +1 more source

Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

Expert Opinion on Investigational Drugs, 2015
N. Esser, N. Paquot, A. Scheen
semanticscholar   +1 more source

Compatibility of Argatroban with Selected Cardiovascular Agents

American Journal of Health-System Pharmacy, 2004
Marcia E. Honisko, Vincent F. Mauro, Jodie M. Fink, Kenneth S. Alexander, Michael Militello   +4 more
openaire   +3 more sources

Cardiovascular Agents

1983
openaire   +2 more sources

Cardiovascular Agents

2008
openaire   +2 more sources

Clinical practice algorithms: Medication management to reduce fall risk in the elderly—Part 3, benzodiazepines, cardiovascular agents, and antidepressants

Journal of the American Academy of Nurse Practitioners, 2008
Tatjana Bulat, S. Castle, Michelle Rutledge, P. Quigley   +3 more
semanticscholar   +1 more source

Cardiovascular Effects of Neuromuscular Blocking Agents

International Anesthesiology Clinics, 1979
John J. Savarese, Daniel M. Philbin
openaire   +3 more sources

Hyperlipidaemia and cardiovascular disease – Newer antihyperglycaemic agents and cardiovascular disease

Current Opinion in Lipidology, 2013
Sony Anthony, Rajesh Peter, Hammad Bajwa
openaire   +3 more sources

Pharmacokinetic data on cardiovascular agents

1992
openaire   +2 more sources